Study Validates ATA Ultrasonographic Thyroid Nodule Risk Assessment

Article

High-risk ultrasound findings strongly indicate that thyroid nodules are malignant, even when nodules are cytologically indeterminate following find needle aspiration.

[[{"type":"media","view_mode":"media_crop","fid":"52177","attributes":{"alt":"Image © Bork / Shutterstock.com","class":"media-image","id":"media_crop_572832058727","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"6473","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":"Image © Bork / Shutterstock.com","typeof":"foaf:Image"}}]]

High-risk ultrasonographic findings strongly indicate that thyroid nodules are malignant, even when nodules are cytologically indeterminate following find needle aspiration (FNA), according to a prospective study presented at the 86th Annual Meeting of the American Thyroid Association (ATA), held September 21-25 in Denver, Colorado. The results were published online in the journal Thyroid.

“This prospective study validates the new ATA sonographic pattern risk assessment for selection of thyroid nodules for [ultrasound] FNA based upon Bethesda cytology and surgical pathology results,” reported Alice Tang, MD, and coauthors.

The ATA sonographic risk-assessment criteria include calcification patterns, nodule echogenicity, size, and shape.

The research team studied ultrasound characteristics of 211 thyroid nodules that had been selected for FNA, assessing cytology using the Bethesda System for Reporting Thyroid Cytopathology. Surgical pathology and cytology reports were used to determine malignancy, and these findings were then compared to ATA sonographic risk estimates.

Examining results for 199 patients (157 women and 42 men), the authors found that cytologically indeterminate nodules with sonographic patterns deemed to be “high risk” (4% of nodules assessed) under the ATA risk assessment system, were indeed determined to be malignant after surgical excision. All of these high-risk nodules were determined to be malignant, compared to nodules in the sonographic intermediate- and low-risk category, 21% and 17% of which turned out to be malignant; only 1% of nodules in the “very low” sonographic risk category were malignant (P = .003).

Nodule size was inversely associated with ATA sonographic risk assessment, with lower-risk nodules being significantly larger than high-risk nodules (P < .0001). Nodule classifications by Bethesda criteria also varied significantly by ATA ultrasound risk assessment categories (P < .0001), the researchers reported.

Reference

Tang A, Falciglia M, Yang H, et al. Highlighted oral 3. Validation of ATA ultrasound risk assessment of thyroid nodules. Thyroid. 2016;26(suppl 1).

Recent Videos
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Related Content